Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8309056 | 0.98 | ALDH1A1 (0.43) | ALDH1A1F2GLAHPGDMTNR1A | |
| SCHEMBL8807051 | 0.88 | PDE4A (0.42) | ALDH1A1F2GLAHPGDPDE4A | |
| SCHEMBL1192693 | 0.83 | MTNR1A (0.47) | ALDH1A1F2GLAHPGDMTNR1A | |
| SCHEMBL2507643 | 0.82 | MAP4K4 (0.55) | ALDH1A1F2GLAHPGD | |
| SCHEMBL591893 | 0.79 | MAPT (0.56) | ALDH1A1HPGDMTNR1AMTNR1BPDE4A | |
| SCHEMBL29923692 | 0.79 | MAPT (0.56) | ALDH1A1HPGDMTNR1AMTNR1BPDE4A | |
| SCHEMBL28810851 | 0.79 | MTNR1A (0.49) | ALDH1A1F2GLAHPGDMTNR1A | |
| SCHEMBL16199847 | 0.78 | ALDH1A1 (0.42) | ALDH1A1F2GLAHPGDMTNR1A | |
| SCHEMBL1999978 | 0.78 | ENPP1 (0.54) | ALDH1A1GLAHPGDPDE4APDE4B | |
| SCHEMBL27956202 | 0.78 | GLA (0.50) | ALDH1A1F2GLAHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206760-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| WO-2025063725-A1 | NOVEL SKELETAL DERIVATIVE EFFECTIVE FOR HER2 MUTATION, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 한미약품 주식회사 | 2025-03-27 | — | — | WO | disclosed |
| EP-4501925-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| US-12171739-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240399001-A1 | RADIOTRACERS AND THERAPEUTICS BINDING TO FIBROBLAST ACTIVATION PROTEIN (FAP) | Blue Earth Diagnostics Limited (GB) | 2024-12-05 | — | — | US | disclosed |
| EP-4366786-A1 | RADIOTRACERS AND THERAPEUTICS BINDING TO FIBROBLAST ACTIVATION PROTEIN (FAP) | Blue Earth Diagnostics Ltd (GB) | 2024-05-15 | — | — | EP | disclosed |
| CN-117836013-A | Radiotracer and therapeutic agents that bind to Fibroblast Activation Protein (FAP) | 蓝地诊断有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-115803326-B | EGFR inhibitor, preparation method thereof and application thereof in pharmacy | 上海和誉生物医药科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20230142839-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2023-05-11 | — | — | US | disclosed |
| CN-115803326-A | EGFR inhibitor, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| EP-0824525-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-02-25 | — | — | EP | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1997030034-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| EP-0782570-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-07-09 | — | — | EP | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| WO-1996033977-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240399001-A1 | RADIOTRACERS AND THERAPEUTICS BINDING TO FIBROBLAST ACTIVATION PROTEIN (FAP) | FAP, FIBP, FGFR1 | ALDH1A1 1672/4885F2 2560/4885GLA 375/4885 |
| US-20230142839-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | ALDH1A1 2816/4885F2 2650/4885GLA 3160/4885 |
| US-20250206760-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | WEE1, WEE2, ERBB2 | ALDH1A1 3477/4885F2 1672/4885GLA 3519/4885 |
| US-12171739-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | ALDH1A1 2816/4885F2 2650/4885GLA 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.